All News

RheumNow Podcast square

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.

Read Article
Psoriasis Severe legs sara

Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis

Jack Cush, MD

Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.

Read Article
PsA, PSO, nail

Two Year Guselkumab Benefits in Psoriatic Arthritis

MedPage Today

Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.

Read Article
RheumNow Podcast square

An Ounce of Prevention (2.4.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout. 

Read Article
xray%20spine%20films_0.jpg

BE MOBILE 1 Study - Bimekizumab in Non-Radiographic Axial Spondyloarthritis

Jack Cush, MD

Today, UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Read Article
RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Read Article
Ixekizumab in 1401 #PSA pts w/ 2248 Pt-Yrs exposure showed Serious AE in 134 pts. Most common AEs were nasopharyngitis & URI. Incidence of SAE (≤1.2/100PY), cancer (0.7/100PY), IBD (0.1/00PY), depression (1.6/100PY) were low. #PSAlways https://t.co/YGGj4XCQDM

Links:

Dr. John Cush RheumNow ( View Tweet)

2020 Pt preferences survey- 137 #PsA pts most took TNFi (30%), IL-17i (20%), MTX (10%). From 2018 to 2020 a signif incr in IL-17i & PDE4 inhib. Pts want Rx for damage (80%), ADL (71%), & pain (70%) https://t.co/2dyIuQubh5 https://t.co/sFbtRj0Lbv

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Review of 5 trials shows ixekizumab with higher rates of complete skin & nail clearance compared H2H against to etanercept, guselkumab, ustekinumab, and adalimumab (Data from IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, & SPIRIT-H2H trials https://t.co/t5wrmE3nbK #PsA #PsAlways https://t.co/MQjgktOZWR

Links:

Dr. John Cush RheumNow ( View Tweet)
Ask Cush Anything! Have a rheumatology question or case for Dr. Cush? Submit it here and we may feature it on an upcoming podcast. https://t.co/KgPIeScthr https://t.co/nk4re9mlcH

Links:

Dr. John Cush RheumNow ( View Tweet)
"Remember bony growth is a feature of the PsA joint and one potential way in which IL17s may target the disease." Dr. B. Kirkham discusses potential synergistic activity of IL17A and TNFi in the SpA joint. #RNL2022 @RheumNow https://t.co/L9uZqoen2w
Dr. Rachel Tate uptoTate ( View Tweet)
IL-17i - Good Long term safety profile and low malignancy risk Best efficacy for nail psoriasis @RheumNow #RNL2022 https://t.co/8T7wAGJChF
Robert B Chao, MD doctorRBC ( View Tweet)
#ClinicalPearl Fun fact According to Dr Strober IL17i have BEST effects on nail involvement in #psoriasis. I didn’t know. often need ⬆️dose over time #RNL2022 @RheumNow https://t.co/Y9U9c4M03j
Janet Pope Janetbirdope ( View Tweet)
Run down on IL-17 inhibitors by Dr Strober @BruceStrober #RNL2022 https://t.co/mqXvfJGhij
Dr. John Cush RheumNow ( View Tweet)
Role of IL17 blockers in creating dysbiosis (expansion of Candida), could that be one of the reasons explaining its effect in SpA and PsA?!! Jose Scher @RheumNow #Rnl2022 https://t.co/AyGgNiDVJ9
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Cellular source of IL17 in SpA Bruce Kirkham @RheumNow #Rnl2022 https://t.co/vDMks0RtBb
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Synergetic effect of IL17 and TNF in PSA. Bruce Kirkham @RheumNow #Rnl2022 https://t.co/acfqiluJWR
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. B. Kirkman reviews research and development timeline for IL17A. I've started explaining this trajectory to patients when discussing "newer" drugs to market that have been around since I was in elementary school. #RNL2022 @RheumNow https://t.co/TgaOYmkBO4
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Kirkman reviews IL12, IL23, and IL17s. #RNL2022 @RheumNow https://t.co/nFHBzrdz2D
Dr. Rachel Tate uptoTate ( View Tweet)
Systematic review of GI Safety of IL-17 inhibitors included 106 RCTs and 40,053 patients. Inflammatory bowel disease occurred in 0.4%; Most freq Sxs - diarrhea (2.5%), nausea or vomiting (0.7%), and gastroenteritis (0.2%). https://t.co/tv3QXHU1Hg

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×